A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable.

Bill 118 s 1522, also known as the "Biosimilar Interchangeability Study Act," is a proposed piece of legislation that aims to mandate the Secretary of Health and Human Services to conduct a comprehensive study on the designation of biosimilar biological products as interchangeable.

Biosimilar biological products are medications that are highly similar to already approved biological products, known as reference products. These biosimilars have the potential to provide more affordable treatment options for patients, as they are typically less expensive than their reference products.

The bill seeks to address the issue of interchangeability, which refers to the ability of a biosimilar to produce the same clinical result as the reference product in any given patient. This designation is important because it allows pharmacists to substitute a biosimilar for the reference product without the need for additional approval from a healthcare provider. The study mandated by this bill would evaluate the current process for designating biosimilar products as interchangeable, including the criteria used to make this determination. It would also assess the impact of interchangeability on patient access to affordable medications and the overall healthcare system. Overall, the Biosimilar Interchangeability Study Act aims to provide valuable information to policymakers and stakeholders on the effectiveness of the current interchangeability designation process and potential improvements that could be made to ensure patients have access to safe and affordable biosimilar medications.